标准化,可扩展,及时灵活的腺相关病毒载体生产使用冷冻高密度HEK-293细胞库和细胞盘。

Q1 Immunology and Microbiology Human Gene Therapy Methods Pub Date : 2019-02-01 DOI:10.1089/hgtb.2018.228
Benjamin Strobel, Kai Zuckschwerdt, Gudrun Zimmermann, Christine Mayer, Ruth Eytner, Philipp Rechtsteiner, Sebastian Kreuz, Thorsten Lamla
{"title":"标准化,可扩展,及时灵活的腺相关病毒载体生产使用冷冻高密度HEK-293细胞库和细胞盘。","authors":"Benjamin Strobel,&nbsp;Kai Zuckschwerdt,&nbsp;Gudrun Zimmermann,&nbsp;Christine Mayer,&nbsp;Ruth Eytner,&nbsp;Philipp Rechtsteiner,&nbsp;Sebastian Kreuz,&nbsp;Thorsten Lamla","doi":"10.1089/hgtb.2018.228","DOIUrl":null,"url":null,"abstract":"<p><p>Adeno-associated virus (AAV) vectors currently represent the most attractive platform for viral gene therapy and are also valuable research tools to study gene function or establish disease models. Consequently, many academic labs, core facilities, and biotech/pharma companies meanwhile produce AAVs for research and early clinical development. Whereas fast, universal protocols for vector purification (downstream processing) are available, AAV production using adherent HEK-293 cells still requires time-consuming passaging and extensive culture expansion before transfection. Moreover, most scalable culture platforms require special equipment or extensive method development. To tackle these limitations in upstream processing, this study evaluated frozen high-density cell stocks as a ready-to-seed source of producer cells, and further investigated the multilayered CELLdisc culture system for upscaling. The results demonstrate equal AAV productivity using frozen cell stock-derived cultures compared to conventionally cultured cells, as well as scalability using CELLdiscs. Thus, by directly seeding freshly thawed cells into CELLdiscs, AAV production can be easily upscaled and efficiently standardized to low-passage, high-viability cells in a timely flexible manner, potentially dismissing time-consuming routine cell culture work. In conjunction with a further optimized iodixanol protocol, this process enabled supply to a large-animal study with two high-yield AAV2 capsid variant batches (0.6-1.2 × 10<sup>15</sup> vector genomes) in as little as 4 weeks.</p>","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":"30 1","pages":"23-33"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hgtb.2018.228","citationCount":"34","resultStr":"{\"title\":\"Standardized, Scalable, and Timely Flexible Adeno-Associated Virus Vector Production Using Frozen High-Density HEK-293 Cell Stocks and CELLdiscs.\",\"authors\":\"Benjamin Strobel,&nbsp;Kai Zuckschwerdt,&nbsp;Gudrun Zimmermann,&nbsp;Christine Mayer,&nbsp;Ruth Eytner,&nbsp;Philipp Rechtsteiner,&nbsp;Sebastian Kreuz,&nbsp;Thorsten Lamla\",\"doi\":\"10.1089/hgtb.2018.228\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Adeno-associated virus (AAV) vectors currently represent the most attractive platform for viral gene therapy and are also valuable research tools to study gene function or establish disease models. Consequently, many academic labs, core facilities, and biotech/pharma companies meanwhile produce AAVs for research and early clinical development. Whereas fast, universal protocols for vector purification (downstream processing) are available, AAV production using adherent HEK-293 cells still requires time-consuming passaging and extensive culture expansion before transfection. Moreover, most scalable culture platforms require special equipment or extensive method development. To tackle these limitations in upstream processing, this study evaluated frozen high-density cell stocks as a ready-to-seed source of producer cells, and further investigated the multilayered CELLdisc culture system for upscaling. The results demonstrate equal AAV productivity using frozen cell stock-derived cultures compared to conventionally cultured cells, as well as scalability using CELLdiscs. Thus, by directly seeding freshly thawed cells into CELLdiscs, AAV production can be easily upscaled and efficiently standardized to low-passage, high-viability cells in a timely flexible manner, potentially dismissing time-consuming routine cell culture work. In conjunction with a further optimized iodixanol protocol, this process enabled supply to a large-animal study with two high-yield AAV2 capsid variant batches (0.6-1.2 × 10<sup>15</sup> vector genomes) in as little as 4 weeks.</p>\",\"PeriodicalId\":13126,\"journal\":{\"name\":\"Human Gene Therapy Methods\",\"volume\":\"30 1\",\"pages\":\"23-33\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1089/hgtb.2018.228\",\"citationCount\":\"34\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Gene Therapy Methods\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/hgtb.2018.228\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Gene Therapy Methods","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/hgtb.2018.228","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
引用次数: 34

摘要

腺相关病毒(AAV)载体是目前最具吸引力的病毒基因治疗平台,也是研究基因功能或建立疾病模型的重要研究工具。因此,许多学术实验室、核心设施和生物技术/制药公司同时生产用于研究和早期临床开发的aav。虽然有快速、通用的载体纯化(下游处理)方案,但使用贴壁的HEK-293细胞生产AAV仍然需要耗时的传代和转染前的大量培养扩增。此外,大多数可扩展的培养平台需要特殊的设备或广泛的方法开发。为了解决上游加工的这些限制,本研究评估了冷冻高密度细胞库作为生产细胞的现成种子来源,并进一步研究了多层CELLdisc培养系统的升级。结果表明,与常规培养的细胞相比,使用冷冻细胞库衍生培养物具有相同的AAV生产力,并且使用celldisc具有可扩展性。因此,通过将新鲜解冻的细胞直接播种到celldisc中,AAV的生产可以很容易地扩大规模,并以及时灵活的方式有效地标准化为低传代、高活力的细胞,从而可能省去耗时的常规细胞培养工作。结合进一步优化的碘沙醇方案,该工艺能够在短短4周内提供两个高产AAV2衣壳变体批次(0.6-1.2 × 1015载体基因组)的大型动物研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Standardized, Scalable, and Timely Flexible Adeno-Associated Virus Vector Production Using Frozen High-Density HEK-293 Cell Stocks and CELLdiscs.

Adeno-associated virus (AAV) vectors currently represent the most attractive platform for viral gene therapy and are also valuable research tools to study gene function or establish disease models. Consequently, many academic labs, core facilities, and biotech/pharma companies meanwhile produce AAVs for research and early clinical development. Whereas fast, universal protocols for vector purification (downstream processing) are available, AAV production using adherent HEK-293 cells still requires time-consuming passaging and extensive culture expansion before transfection. Moreover, most scalable culture platforms require special equipment or extensive method development. To tackle these limitations in upstream processing, this study evaluated frozen high-density cell stocks as a ready-to-seed source of producer cells, and further investigated the multilayered CELLdisc culture system for upscaling. The results demonstrate equal AAV productivity using frozen cell stock-derived cultures compared to conventionally cultured cells, as well as scalability using CELLdiscs. Thus, by directly seeding freshly thawed cells into CELLdiscs, AAV production can be easily upscaled and efficiently standardized to low-passage, high-viability cells in a timely flexible manner, potentially dismissing time-consuming routine cell culture work. In conjunction with a further optimized iodixanol protocol, this process enabled supply to a large-animal study with two high-yield AAV2 capsid variant batches (0.6-1.2 × 1015 vector genomes) in as little as 4 weeks.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Human Gene Therapy Methods
Human Gene Therapy Methods BIOTECHNOLOGY & APPLIED MICROBIOLOGY-GENETICS & HEREDITY
CiteScore
5.80
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases. The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.
期刊最新文献
Lot-to-Lot Variation in Adeno-Associated Virus Serotype 9 (AAV9) Preparations. Fast-Seq: A Simple Method for Rapid and Inexpensive Validation of Packaged Single-Stranded Adeno-Associated Viral Genomes in Academic Settings. LINC00958 Accelerates Cell Proliferation and Migration in Non-Small Cell Lung Cancer Through JNK/c-JUN Signaling. Nanoparticle Tracking of Adenovirus by Light Scattering and Fluorescence Detection. LINC00958 accelerates cell proliferation and migration in non-small cell lung cancer through JNK/c-JUN signaling.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1